Holen Sie sich die Stockscreener-App
0.4101
4.37%
-0.0203
Schlusskurs vom Vortag:
$0.4304
Offen:
$0.447
24-Stunden-Volumen:
74,539
Relative Volume:
0.03
Marktkapitalisierung:
$4.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.90%
1M Leistung:
-30.59%
6M Leistung:
-99.43%
1J Leistung:
-99.89%
1-Tages-Spanne:
$0.41
$0.447
1-Wochen-Bereich:
$0.3795
$0.4797
52-Wochen-Spanne:
$0.375
$402.48
AEON Biopharma Inc. Stock (AEON) Company Profile
Firmenname
AEON Biopharma Inc.
Sektor
Branche
Telefon
(949) 354-6499
Adresse
5 Park Plaza, Suite 1750, Irvine
Vergleichen Sie AEON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.4101 | 4.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
494.63 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.38 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.10 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.75 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.28 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | H.C. Wainwright | Buy |
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com India
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com
Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com
AEON Biopharma announces CEO appointment - MSN
AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa
Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com
AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks
Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus
AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times
AEON Biopharma names Rob Bancroft as new CEO - Investing.com
AEON Biopharma Appoints New CEO Rob Bancroft: Inside the $1M+ Executive Compensation Deal - Stock Titan
Former Revance Therapeutics Leader Takes AEON Helm: Inside the Race to Challenge BOTOX's $3B Market - Stock Titan
AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks
AEON Biopharma announces new interim CEO and CFO - Investing.com
Trading Day Triumph: AEON Biopharma Inc (AEON) Ends at 0.42, a -10.60 Surge/Plunge - DWinneX
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
AEON Biopharma Inc (AEON) Stock: The Story of a 52-Week Stock Range - investchronicle.com
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1 - NewsBreak: Local News & Alerts
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma Announces CEO Transition - The Manila Times
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - insights.citeline.com
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025 - Nasdaq
AEON's $20M Cash Injection Powers Game-Changing BOTOX Alternative Development - Stock Titan
AEON Biopharma (NASDAQ:AEON) Stock Price Down 7.6% – Should You Sell? - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Understanding AEON’s financial ratios: A beginner’s guide - US Post News
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma : Corporate Presentation -March 10, 2025 at 06:26 am EDT - Marketscreener.com
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference - The Manila Times
AEON CEO to Showcase Botulinum Toxin Pipeline at Major Healthcare Conference - StockTitan
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
Cervical Dystonia Market Expected to Experience Major Growth - openPR
AEON stock touches 52-week low at $0.76 amid market shifts - Investing.com
Finanzdaten der AEON Biopharma Inc.-Aktie (AEON)
Es liegen keine Finanzdaten für AEON Biopharma Inc. (AEON) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
Kapitalisierung:
|
Volumen (24h):